Two Sigma Securities’s ALX Oncology ALXO Stock Holding History

Two Sigma Securities’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22K	Buy	+10,993	New	+$20.9K	﹤0.01%	1360

Other funds holding ALXO

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Two Sigma Securities's ALXO Position: Q1 2026 in Review

Two Sigma Securities opened a new position in ALX Oncology (ALXO) in Q1 2026: 10,993 shares worth $22K. The stake represents ﹤0.01% of the portfolio and ranks #1360 among its holdings.

69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

Two Sigma Securities held 10,993 shares of ALX Oncology worth $22K as of Q1 2026.
ALX Oncology was a new Two Sigma Securities position in Q1 2026.
ALX Oncology made up ﹤0.01% of Two Sigma Securities's portfolio in Q1 2026, its #1360 holding.
69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.